Search Results - "Moldawer, Nancy"

Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients by Wood, Laura S, Moldawer, Nancy P, Lewis, Colleen

“…Immune checkpoint inhibitor (ICI) therapy is a fast-developing field within the spectrum of cancer care. ICIs are associated with distinctive immune-related…”
Get full text

The Critical Role of the Oncology Nurse as a Partner in the Management of Patients With Advanced Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care by Moldawer, Nancy P., Wood, Laura S.

“…The treatment of advanced renal cell carcinoma has changed dramatically since 2005 with the approval of 12 regimens including oral, intravenous, and…”
Get full text

Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer by Marshall, Catherine H, Fu, Wei, Wang, Hao, Park, Jong Chul, DeWeese, Theodore L, Tran, Phuoc T, Song, Daniel Y, King, Serina, Afful, Michaella, Hurrelbrink, Julia, Manogue, Charlotte, Cotogno, Patrick, Moldawer, Nancy P, Barata, Pedro C, Drake, Charles G, Posadas, Edwin M, Armstrong, Andrew J, Sartor, Oliver, Antonarakis, Emmanuel S

“…To investigate whether radium-223 increases peripheral immune responses to sipuleucel-T in men with bone-predominant, minimally symptomatic metastatic…”
Get full text

Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus by Creel, Patricia, Moldawer, Nancy P

Get full text

Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications by Moldawer, Nancy P, Figlin, Robert

“…To provide an overview of the current knowledge and treatment options for renal cell carcinoma (RCC). Published articles, published abstracts, online…”
Get full text

Mathematical Model to Predict Individual Survival for Patients With Renal Cell Carcinoma by Zisman, A.

Get full text

A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma by GITLITZ, Barbara J, BELLDEGRUN, Arie S, ZISMAN, Amnon, CHAO, Debby H, PANTUCK, Tallan J, HINKEL, Andreas, MULDERS, Peter, MOLDAWER, Nancy, TSO, Cho-Lea, FIGLIN, Robert A

Get full text

Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit by Smith, Bethany N., Mishra, Rajeev, Billet, Sandrine, Placencio-Hickok, Veronica R., Kim, Minhyung, Zhang, Le, Duong, Frank, Madhav, Anisha, Scher, Kevin, Moldawer, Nancy, Oppenheim, Amy, Angara, Bryan, You, Sungyong, Tighiouart, Mourad, Posadas, Edwin M., Bhowmick, Neil A.

“…Androgen receptor signaling inhibitors (ARSIs) are standard of care for advanced prostate cancer (PCa) patients. Eventual resistance to ARSIs can include the…”
Get full text

The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma by Parreira, Sara, Burns, Kathleen, Moldawer, Nancy, Zomordian, Nazy, Bandali, Nesan, Virdee, Kiran, Walsh, Meghara, Kelly, Daniel, Rao, Dharanija, Teresi, Rosemary, Wood, Laura S.

“…The recent approval of first-line tyrosine kinase inhibitor plus immuno-oncology agent combination therapy for the treatment of advanced renal cell carcinoma…”
Get full text

Immune Checkpoint Inhibitor Therapy by Wood, Laura S, Moldawer, Nancy P, Lewis, Colleen

“…BACKGROUND: Immune checkpoint inhibitor (ICI) therapy is a fast-developing field within the spectrum of cancer care. ICIs are associated with distinctive…”
Get full text

Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC) by Marshall, Catherine Handy, Park, Jong Chul, DeWeese, Theodore L., King, Serina, Afful, Michaella, Hurrelbrink, Julia, Manogue, Charlotte, Cotogno, Patrick, Moldawer, Nancy P., Barata, Pedro C., Drake, Charles G., Posadas, Edwin M., Armstrong, Andrew J., Sartor, A. Oliver, Antonarakis, Emmanuel S.

“…Abstract only 130 Background: SipT-induced antigen-specific immune responses in mCRPC patients correlate with survival. Due to the immunomodulatory effects of…”
Get full text

Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer by Marshall, Catherine Handy, Park, Jong Chul, Fu, Wei, Wang, Hao, DeWeese, Theodore L., King, Serina, Afful, Michaella, Hurrelbrink, Julia, Manogue, Charlotte, Cotogno, Patrick, Moldawer, Nancy P., Barata, Pedro C., Drake, Charles G., Posadas, Edwin Melencio, Armstrong, Andrew J., Sartor, A. Oliver, Antonarakis, Emmanuel S.

“…Abstract only 5563 Background: It has been suggested that immune modulation can be augmented by radiation, possibly by enhancing tumor-antigen display…”
Get full text

A phase 2 study of cabozantinib in metastatic castrate resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies by Posadas, Edwin M., Scher, Kevin, Chen, Jie-Fu, Sievert, Margarit, Oppenheim, Amy, Moldawer, Nancy P., Knudsen, Beatrice, Freeman, Michael, Bhowmick, Neil, Rogatko, Andre, Tseng, Hsian-Rong, Chung, Leland WK, Figlin, Robert A.

“…Abstract only…”
Get full text

Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases by Posadas, Edwin M., Chen, Jie-Fu, Tripathi, Manisha, Lu, Yi-Tsung, Montes, Alexander, Go, Ann, Ureno, Alexander, Cavassani, Karen Angelica, Sievert, Margarit, Rogatko, Andre, Limvorasak, Suwicha, Oppenheim, Amy, Moldawer, Nancy P., Chung, Leland WK, Bhowmick, Neil, Tseng, Hsian-Rong, Figlin, Robert A.

“…Abstract only 5031 Background: The presence of VM in metastatic, castration-resistant prostate cancer (mCRPC) predicts poor survival. Cabozantinib (cabo) is a…”
Get full text

A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies by Huynh, Richard, Chen, Jie-Fu, Tighiouart, Mourad, Sievert, Margarit, Oppenheim, Amy, Moldawer, Nancy P., Knudsen, Beatrice, Freeman, Michael, Bhowmick, Neil, Rogatko, Andre, Tseng, Hsian-Rong, Chung, Leland WK, Scher, Kevin, Figlin, Robert A., Posadas, Edwin M.

“…Abstract only 208 Background: Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that has recognized clinical activity in mCRPC. While phase 3…”
Get full text

A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes by Posadas, Edwin M., Tighgohart, Mourad, LU, YI-TSUNG, Di Vizio, Dolores, Hoffman, David M. J., Green, Leland, Sievert, Margarit, Oppenheim, Amy, Moldawer, Nancy P., Knudsen, Beatrice, Freeman, Michael, Bhowmick, Neil, Rogatko, Andre, Tseng, Hsian-Rong, Chung, Leland WK, Figlin, Robert A.

“…Abstract only…”
Get full text

Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy by RECKAMP, Karen L, FIGLIN, Robert A, MOLDAWER, Nancy, PANTUCK, Allan J, BELLDEGRUN, Arie S, BURDICK, Marie D, STRIETER, Robert M

“…Chemokines play an important role in regulating tumor-mediated immunity, angiogenesis, and tumor cell metastasis. The chemokine receptor, CXCR3, is expressed…”
Get full text

A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma by Gitlitz, Barbara J, Belldegrun, Arie S, Zisman, Amnon, Chao, Debby H, Pantuck, Allan J, Hinkel, Andreas, Mulders, Peter, Moldawer, Nancy, Tso, Cho-Lea, Figlin, Robert A

“…Cultured tumor lysate-loaded dendritic cells (TuLy-DC) have been demonstrated in vitro to stimulate potent immune modulations and generate significant…”
Get full text

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor by Figlin, R A, Pierce, W C, Kaboo, R, Tso, C L, Moldawer, N, Gitlitz, B, deKernion, J, Belldegrun, A

“…Metastatic renal cell carcinoma is a disease with a mean survival of 6 to 10 months. Interleukin-2 (IL-2), the only approved therapy for metastatic renal cell…”
Get more information

CE Credit: The Promise of Recombinant Interleukin-2 by Moldawer, Nancy, Carr, Ellen

Get full text